Decrypt Biomedicine
New York · Founded 2022
About Decrypt Biomedicine
Decrypt Biomedicine develops small-molecule drugs targeting cryptic binding sites on proteins.
Company Facts
- Founded: 2022
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Funding stage: Seed
- Last round: Seed (Dec 2022)
- Website: decrypt.bio
Social Profiles
Canonical: https://fsome.com/organization/decrypt-biomedicine-8439200 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.